Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli

Patent metadata

Field	Value
Publication number	US-11701398-B2
Application number	US-202016893106-A
Country	US
Kind code	B2
Filing date	Jun 4, 2020
Priority date	Jun 4, 2020
Publication date	Jul 18, 2023
Grant date	Jul 18, 2023

Abstract

A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.

First claim

What is claimed is:

1. A composition for treating an infection or disease caused by a pathogenic Escherichia coli comprising:
a Podoviridae bacteriophage Esc-COP-30 (deposited in the Korean Collection for Type Cultures (KCTC) under accession number Accession number: KCTC 14032BP) having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1, and
a pharmaceutically acceptable carrier,
wherein the Podoviridae bacteriophage Esc-COP-30 has a concentration of 1×10 4 pfu/ml to 1×10 15 pfu/ml or 1×10 4 pfu/g to 1×10 15 pfu/g, and
wherein the composition is adapted for treating the infection or disease caused by the pathogenic Escherichia coli.

2. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.

3. The composition of claim 1 further comprising:
one or more selected from the group consisting of a lubricant, a wetting agent, a sweetener, a flavor, an emulsifier, a suspending agent, and a preservative.

4. The composition of claim 1 , wherein the pathogenic Escherichia coli is enterohemorrhagic Escherichia coli , enterotoxigenic Escherichia coli , enteroinvasive Escherichia coli , enteropathogenic Escherichia coli , enteroaggregative Escherichia coli , or carcinogenic Escherichia coli.

5. The composition of claim 1 , wherein the infection or disease is food poisoning, gastroenteritis, diarrhea, urinary tract infections, neonatal meningitis, hemolytic-uremic syndrome, peritonitis, mastitis, septicemia, Gram-negative pneumonia, shigellosis, dysentery, or cancer.

6. The composition of claim 1 , wherein the composition is a solution, suspension, emulsion in oil, water-soluble medium, extract, powder, granule, tablet, or capsule.

7. The composition of claim 1 , wherein the Podoviridae bacteriophage Esc-COP-30 has major structural proteins in the sizes of approximately 43 kDa, 48 kDa, 63 kDa, 75 kDa, 85 kDa, and 142 kDa.

8. The composition of claim 1 , wherein the Podoviridae bacteriophage Esc-COP-30 has a latent period of 10-25 minutes and a burst size of 740-860 PFU/infected cell.

9. The composition of claim 8 , wherein the latent period is 15-20 minutes and the burst size of 770-830 PFU/infected cell.

10. The composition of claim 1 further comprising:
a second bacteriophage having an ability to lyse a pathogenic Escherichia coli or a non- Escherichia coli bacterial species.

11. A method for treating an infection or disease caused by a pathogenic Escherichia coli , comprising:
administering to a subject a Podoviridae bacteriophage Esc-COP-30 (deposited in the Korean Collection for Type Cultures (KCTC) under accession number Accession number: KCTC 14032BP) having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1; and
lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage,
wherein the Podoviridae bacteriophage Esc-COP-30 has a concentration of 1×10 4 pfu/ml to 1×10 15 pfu/ml or 1×10 4 pfu/g to 1×10 15 pfu/g.

Assignees

• Intron Biotechnology Inc

Inventors

• Yoon Seong Jun
• Son Jee Soo
• Kim In Hwang
• Paik Hyoung Rok
• Im Hyun Joo
• Yu Hyun Jin
• Kim Beom Seok
• Lee Geun Woo
• Jun Soo Youn
• Kang Sang Hyeon

Classifications

• A61K35/76 Primary

  Viruses; Subviral particles; Bacteriophages · CPC title

• A61P31/04 Primary

  Antibacterial agents · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2795/10221

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2795/10232

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title